Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
Vincenti
F
F
University of California, San Francisco 94143, USA.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019703:Calcineurin / Q000276:immunology; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic / Q000379:methods; D016572:Cyclosporine / Q000627:therapeutic use; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000145:classification / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000077561:Daclizumab; D019703:Calcineurin; D009173:Mycophenolic Acid; D011241:Prednisone